The present disclosure relates generally to fluid delivery systems and methods, and, in particular, to a system and method for performing an injection using a fluid delivery system with dynamic pressure control of two or more fluids during an injection protocol.
In many medical diagnostic and therapeutic procedures, a medical practitioner, such as a physician, injects a patient with one or more medical fluids. In recent years, a number of fluid delivery systems having injector-actuated syringes and fluid injectors for pressurized injection of fluids, such as a contrast solution (often referred to simply as “contrast”), a flushing agent, such as saline, and other medical fluids have been developed for use in procedures such as angiography, computed tomography (CT), ultrasound, magnetic resonance imaging (MRI), positron emission tomography (PET), and other imaging procedures. In general, these fluid delivery systems are designed to deliver a preset amount of fluid at a desired flow rate. Typically, for a multiphase injection, fluid is delivered in a contrast phase followed by a saline flush phase. The contrast fluid provides enhancement to diagnostic images and the saline phase increases contrast flux and provides a sharp distinction with the contrast.
Differences between desired flow rate and fluid volume may be especially apparent for multiphase injections, in which two or more fluids are delivered from two or more syringes which are independently driven by a drive member of a fluid injector in a sequential fashion. Therefore, when performing a multiphase injection, it is important to consider the manner in which the fluid for the two phases is contained. If the fluid reservoirs or syringes are connected in an open system then the pressure in the two fluid locations is expected to be roughly the same during an injection due to fluid communication between the two or more syringes. However, in an open system containing two reservoirs or syringes, development of pressure in the reservoir or syringe containing the first fluid may result in fluid movement from the first reservoir to the second reservoir or syringe depending on the system compliance. This may result in unintended mixing. Such mixing may be permissible for single patient systems; however, cross contamination of the fluid reservoirs may be unacceptable for multi-patient devices.
To isolate the multiple fluid reservoirs and prevent mixing, fluid delivery systems can be constructed using a valve, such as a check valve, stopcock, or fluid manifold, to isolate respective fluid reservoirs and/or syringes. Isolating the fluid reservoirs prevents passive cross contamination of the fluid reservoirs. However, isolating fluid reservoirs can reduce or cause fluctuations in actual flow rate through a fluid delivery system in the absence of any correction or compensation. For example, actual fluid flow rates may be reduced because the second or saline fluid must be driven through the system with enough pressure to drive the first phase and to remove any slack introduced into the system during the first phase of the injection.
Accordingly, there is a need in the art for improved methods and systems for monitoring and controlling fluid flow rate through a fluid delivery system including multiple syringes or fluid reservoirs. For example, such systems may address problems of controlling flow rate through the system and preventing cross contamination of fluids contained in different syringes or reservoirs. The systems and methods disclosed herein are adapted to address such issues.
Various examples of the present disclosure describe methods and fluid injector systems including dynamic pressure control, including pressure control or equalization between fluid in two or more reservoirs, in a fluid delivery system during a multiphase/multi-fluid injection includes providing a multiphase fluid delivery system having at least a first fluid reservoir configured for containing a first fluid, at least a second fluid reservoir configured for containing a second fluid, a fluid conduit for conducting fluid from the first reservoir and the second reservoir to a patient, and an injector having at least a first drive member for expelling fluid from the first reservoir and at least a second drive member for expelling fluid from the second reservoir.
Various embodiments of the present disclosure provide methods for dynamic pressure and fluid flow control. In certain embodiments, the method comprises advancing the first drive member to expel the first fluid from the first reservoir into the conduit during a first injection phase, wherein the first fluid is pressurized to a first fluid pressure. The method then includes measuring the first fluid pressure during the first injection phase to provide a target value, wherein the target value is based at least on the measured fluid pressure of the first fluid phase. After the target value is determined and while the second reservoir is in fluid isolation from the conduit, the method includes advancing or retracting the second drive member to increase or decrease the fluid pressure of the second fluid in the second reservoir to the target value. The first reservoir and the second reservoir may be placed in fluid isolation from the conduit by closing a valve, such as a stopcock, pinch valve, high pressure crack valve, etc. The method then includes placing the second reservoir in fluid communication with the conduit and advancing the second drive member to expel the second fluid from the second reservoir into the conduit at a pressure equal to the target value.
According to various embodiments, the target value may be substantially equal to the first fluid pressure. In other embodiments, the target value may be greater than the first fluid pressure. In other embodiments, the target value may be less than the first fluid pressure. The target value may be determined by a processor associated with the fluid injector based on the specific fluid injection parameters and protocol, for example by calculation of the target value based on various factors, such as desired flow rates of the first fluid and second fluid, fluid types (e.g., contrast versus saline), system capacitance, whether dual flow injection is desired, whether backflow may be an issue, among other factors.
In certain embodiments, the step of advancing the second drive member to expel the second fluid from the second reservoir may further comprise continuing to advance the first drive member to expel the first fluid from the first reservoir to provide a dual flow fluid delivery of a predetermined ratio of the first fluid and the second fluid. The predetermined ratio may be a specified ratio ranging from 1:99 of the first fluid to the second fluid to 99:1 of the first fluid to the second fluid that may be pre-programmed into the processor by a user for a certain injection protocol.
In other embodiments, the method may further comprise isolating the first reservoir from fluid communication with the conduit prior to placing the second fluid reservoir in fluid communication with the conduit or, alternatively, prior to advancing the second drive member to expel the second fluid from the second reservoir in to the conduit. According to these embodiments, the injection protocol may include transitioning the injection from the first fluid to the second fluid while avoiding fluctuations in fluid flow during the transition, for example when there is a difference in viscosity between the first fluid and the second fluid (such as a contrast media which can range from 2.0 to 30.0 cP (at 20° C.), to a lower viscosity fluid, such as saline having a viscosity of 1.0 to 1.5 cP (at 20° C.)), or avoiding backflow of the second fluid into the first fluid reservoir, or vice versa. In various embodiments, the first fluid may be a contrast imaging agent, such as a CT contrast, a CV contrast, an MR contrast, or a PET contrast; and the second fluid may be a flushing fluid, such as saline, Ringer's lactate, water, etc. Alternatively, the first fluid may be a flushing agent and the second fluid may be a contrast, as described herein.
According to other embodiments, the fluid injector may further comprise at least a third fluid reservoir in selectable fluid communication with the conduit and operatively engaged with at least a third drive member of the fluid injector for expelling at least a third fluid into the conduit. The third fluid may be the same or different that the first fluid and/or the second fluid.
In other embodiments, the present disclosure provides a fluid delivery system configured for dynamic pressure control during a multiphase/multi-fluid injection, where the fluid delivery system comprises: at least a first reservoir configured for containing a first fluid; at least a second reservoir configured for containing a second fluid; a conduit connected to the first reservoir and the second reservoir for conducting fluid from the reservoirs to a patient; a fluid injector having at least a first drive member for expelling fluid from the first reservoir and at least a second drive member for expelling fluid from the second reservoir; and a controller in electronic communication with the fluid injector including computer readable memory. The controller may be associated with the fluid injector, a stand-alone operating computer, a removable operating storage media, a hospital information network, or outside computer. The memory includes instructions that when executed by the controller cause the controller to: instruct the injector to advance the first drive member to expel the first fluid from the first reservoir during a first injection phase, wherein the first fluid is pressurized to a first fluid pressure; measure the first fluid pressure during the first injection phase to provide a target value, wherein the target value is based on the measured fluid pressure of the first fluid phase; while the second reservoir is in fluid isolation from the conduit, instruct the injector to advance the second drive member to increase the fluid pressure of the second fluid in the second reservoir to the target value; instruct the injector to place the second reservoir in fluid communication with the conduit; and instruct the injector to advance the second drive member to expel the second fluid from the second reservoir into the conduit at a pressure equal to the target value. The fluid delivery system may be programmed to or optionally generate and display a notification instructing the user to establish fluid communication between the second reservoir and the conduit. Other programmed instructions within the processor are described herein.
Clause 1. A method for dynamic pressure control in a fluid delivery system during a multiphase/multi-fluid injection, comprising: providing a multiphase fluid delivery system comprising at least a first fluid reservoir configured for containing a first fluid, at least a second fluid reservoir configured for containing a second fluid, a fluid conduit for conducting the first fluid from the first reservoir and the second fluid from the second reservoir to a patient, and an injector comprising at least a first drive member for expelling the first fluid from the first reservoir and at least a second drive member for expelling the second fluid from the second reservoir; advancing the first drive member to expel the first fluid from the first reservoir into the conduit during a first injection phase, wherein the first fluid is pressurized to a first fluid pressure; measuring the first fluid pressure during the first injection phase to provide a target value, wherein the target value is based on the measured fluid pressure of the first fluid phase; while the second reservoir is in fluid isolation from the conduit, advancing or retracting the second drive member to increase or decrease the fluid pressure of the second fluid in the second reservoir to the target value; placing the second reservoir in fluid communication with the conduit; and advancing the second drive member to expel the second fluid from the second reservoir into the conduit at a pressure equal to the target value. The second drive member may be advanced to expel the second fluid from the second reservoir to provide a pressure equal to a target value for at least the initial portion of the second fluid.
Clause 2. The method of clause 1, further comprising isolating the first reservoir from fluid communication with the conduit prior to advancing the second drive member to expel the second fluid from the second reservoir into the conduit.
Clause 3. The method of clause 1 or 2, wherein the target value is substantially equal to the first fluid pressure.
Clause 4. The method of clause 1 or 2, wherein the target value is greater than the first fluid pressure.
Clause 5. The method of clause 1 or 2, wherein the target value is less than the first fluid pressure.
Clause 6. The method of any one of clauses 1 to 5, wherein advancing the second drive member further comprises continuing to advance the first drive member to expel the first fluid from the first reservoir to provide a dual flow fluid delivery of a predetermined ratio of the first fluid and the second fluid.
Clause 7. The method of clause 6, further comprising adjusting the first fluid pressure and the second fluid pressure to provide the dual flow fluid delivery, wherein the predetermined ratio is a specified ratio ranging from 1:99 of the first fluid to the second fluid to 99:1 of the first fluid to the second fluid.
Clause 8. The method of any one of clauses 1 to 7, wherein the first fluid comprises an imaging contrast media and the second fluid comprises saline.
Clause 9. The method of any one of clauses 1 to 8, wherein the first fluid reservoir and the at least the second fluid reservoir are fluid reservoirs independently selected from the group consisting of a syringe, a peristaltic pump, and a compressible bag.
Clause 10. The method of any one of clauses 1 to 9, wherein at least one of the first fluid reservoir and the at least the second fluid reservoir is a syringe.
Clause 11. The method of any one of clauses 1 to 10, wherein the first fluid reservoir and the at least the second fluid reservoir are syringes.
Clause 12. The method of any one of clauses 1 to 11, further comprising at least one third fluid reservoir in selectable fluid communication with the conduit and operatively engaged with at least one third drive member of the fluid injector for expelling at least a third fluid into the conduit.
Clause 13. The method of any one of clauses 1 to 12, wherein each fluid reservoir is independently in selective fluid communication with the conduit by a respective valve.
Clause 14. The method of clause 13, wherein each of the respective valves comprises a first, fill position wherein the fluid reservoir is in fluid communication with a fluid container but in fluid isolation with the conduit, a second, closed position wherein the fluid reservoir is in fluid isolation with the respective fluid container and the conduit, and a third, delivery position where the fluid reservoir is in fluid communication with the conduit but in fluid isolation with the fluid container.
Clause 15. The method of clause 13 or 14, wherein each of the respective valves is operatively controlled by a processor of the fluid injector.
Clause 16. A fluid delivery system configured for dynamic pressure control during a multiphase/multi-fluid injection, comprising: at least a first reservoir configured for containing a first fluid; at least a second reservoir configured for containing a second fluid; a conduit connected to the first reservoir and the second reservoir for conducting fluid from the first and second reservoirs to a patient; a fluid injector comprising at least a first drive member for expelling the first fluid from the first reservoir and at least a second drive member for expelling the second fluid from the second reservoir; and a controller in electronic communication with the fluid injector comprising computer readable memory containing instructions that, when executed by the controller, causes the controller to: instruct the injector to advance the first drive member to expel the first fluid from the first reservoir during a first injection phase, wherein the first fluid is pressurized to a first fluid pressure; measure the first fluid pressure during the first injection phase to provide a target value, wherein the target value is based on the measured fluid pressure of the first fluid phase; while the second reservoir is in fluid isolation from the conduit, instruct the injector to advance the second drive member to increase the fluid pressure of the second fluid in the second reservoir to the target value; instruct the injector to place the second reservoir in fluid communication with the conduit; and instruct the injector to advance the second drive member to expel the second fluid from the second reservoir into the conduit at a pressure equal to the target value.
Clause 17. The fluid delivery system of clause 16, wherein the controller comprises further computer readable memory containing instructions that, when executed by the controller, causes the controller to: instruct the injector to isolate the first fluid reservoir from fluid communication with the conduit prior to instructing the injector to advance the second drive member to expel the second fluid from the second reservoir into the conduit.
Clause 18. The fluid delivery system of clause 16, wherein the controller comprises further computer readable memory containing instructions that, when executed by the controller, causes the controller to: concurrent with instructing the injector to advance the second drive member to expel the second fluid, instruct the injector to continue to advance the first drive member to expel the first fluid from the first reservoir to provide a dual flow fluid delivery of a predetermined ratio of the first fluid and the second fluid.
Clause 19. The fluid delivery system of clause 18, wherein the controller comprises further computer readable memory containing instructions that, when executed by the controller, causes the controller to: during the dual flow fluid delivery, instruct the fluid injector to adjust the first fluid pressure and the second fluid pressure to provide the dual flow fluid delivery, wherein the predetermined ratio is a specified ratio ranging from 1:99 of the first fluid to the second fluid to 99:1 of the first fluid to the second fluid.
Clause 20. The fluid delivery system of any one of clauses 16 to 19, wherein the first fluid reservoir and the at least the second fluid reservoir are fluid reservoirs independently selected from the group consisting of a syringe, a peristaltic pump, and a compressible bag.
Clause 21. The fluid delivery system of any one of clauses 16 to 20, wherein at least one of the first fluid reservoir and the at least the second fluid reservoir is a syringe.
Clause 22. The fluid delivery system of any one of clauses 16 to 21, wherein the first fluid reservoir and the at least the second fluid reservoir are syringes.
Clause 23. The fluid delivery system of any one of clauses 16 to 22, wherein the fluid injector further comprises at least one third fluid reservoir in selectable fluid communication with the conduit and operatively engaged with at least one third drive member of the fluid injector for expelling at least a third fluid into the conduit.
Clause 24. The fluid delivery system of any of clauses 16 to 23, wherein each fluid reservoir is independently in selective fluid communication with the conduit by a respective valve.
Clause 25. The fluid delivery system of any of clauses 16 to 24, wherein each of the respective valves comprises a first, fill position wherein the fluid reservoir is in fluid communication with a fluid container but in fluid isolation with the conduit, a second, closed position wherein the fluid reservoir is in fluid isolation with the respective fluid container and the conduit, and a third, delivery position where the fluid reservoir is in fluid communication with the conduit but in fluid isolation with the fluid container.
Clause 26. The fluid delivery system of clause 24 or 25, wherein each of the respective valves is operatively controlled by a processor of the fluid injector.
These and other features and characteristics of a fluid delivery system and fluid injector for performing an injection with dynamic pressure control, as well as the methods of operation and functions of the related elements of structures and the combination of parts and economies of manufacture, will become more apparent upon consideration of the following description and the appended claims with reference to the accompanying drawings, all of which form a part of this specification, wherein like reference numerals designate corresponding parts in the various figures. It is to be expressly understood, however, that the drawings are for the purpose of illustration and description only.
As used in the specification and the claims, the singular form of “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise.
For purposes of the description hereinafter, the terms “upper”, “lower”, “right”, “left”, “vertical”, “horizontal”, “top”, “bottom”, “lateral”, “longitudinal”, and derivatives thereof shall relate to the disclosure as it is oriented in the drawing figures.
Spatial or directional terms, such as “left”, “right”, “inner”, “outer”, “above”, “below”, and the like, are not to be considered as limiting as the invention can assume various alternative orientations.
All numbers used in the specification and claims are to be understood as being modified in all instances by the term “about”. The term “about” means a range of plus or minus ten percent of the stated value.
Unless otherwise indicated, all ranges or ratios disclosed herein are to be understood to encompass any and all subranges or sub-ratios subsumed therein. For example, a stated range or ratio of “1 to 10” should be considered to include any and all subranges between (and inclusive of) the minimum value of 1 and the maximum value of 10; that is, all subranges or sub-ratios beginning with a minimum value of 1 or more and ending with a maximum value of 10 or less, such as but not limited to, 1 to 6.1, 3.5 to 7.8, and 5.5 to 10.
The term “at least” means “greater than or equal to”.
The term “includes” is synonymous with “comprises”.
When used in relation to a syringe and/or a plunger, the term “proximal” refers to a portion of a syringe and/or a plunger nearest a fluid injector when a syringe and/or a plunger is oriented for connecting to a fluid injector. The term “distal” refers to a portion of a syringe and/or a plunger farthest away from a fluid injector when a syringe and/or a plunger is oriented for connecting to a fluid injector. The term “radial” refers to a direction in a cross-sectional plane normal to a longitudinal axis of a syringe, a plunger, and/or a piston extending between proximal and distal ends. The term “circumferential” refers to a direction around an inner or outer surface of a sidewall of a syringe, a plunger, and/or a piston. The term “axial” refers to a direction along a longitudinal axis of a syringe, a piston, and/or a piston extending between the proximal and distal ends. The term “open” when used to refer to a fluid delivery component means that the system is in fluid connection with an outlet, for example through a nozzle or the open end of a tubing component or catheter. In an open system, fluid flow may be constrained, for example by forcing a fluid through a small diameter fluid path where flow may be determined by physical parameters of the system and the fluid, such as tubing diameter, fluid path constrictions, applied pressure, viscosity, etc. The term “closed” when used to refer to a fluid delivery component means that the system is not in fluid connection with an outlet, for example where fluid flow is stopped by a valve, such as a stopcock, high crack pressure valve, pinch valve, and the like. As used herein the term “slack” means mechanical slack, including a clearance or lost motion in a mechanism caused by gaps between parts, compression of mechanical components under applied load (such as by applied pressure), deflection of mechanical components under applied load (such as by applied pressure), that results in a delay of pressurized delivery of a fluid from a fluid injection after application of force.
It is to be understood that the disclosure may assume alternative variations and step sequences, except where expressly specified to the contrary. It is also to be understood that the specific devices and processes illustrated in the attached drawings, and described in the following specification, are simply exemplary embodiments of the disclosure. Hence, specific dimensions and other physical characteristics related to the examples disclosed herein are not to be considered as limiting.
Characterizing an impedance of a fluid delivery system to minimize a difference between desired and actual fluid delivery system performance requires consideration how energy from an energy source is used in or moves through the system. The energy output or loss from the fluid delivery system may be in the form of heat losses through frictional forces or of work done on the fluid delivery system. For example, some of the energy carried by the pressurized fluid as it is delivered under pressure through a catheter is lost through resistive, frictional, or dissipative heating of the fluid. Additionally, pressurized delivery of fluid can also increase the potential energy of the system in terms of an increase in overall volume of system components or compressive forces on system components, as discussed herein. Furthermore, the kinetic energy of pressurized fluid moving through the fluid delivery system can affect the overall performance of the fluid delivery system. For example, inertial forces of moving contrast material and expansion of the containers and/or tubing associated with the system may cause a phase lag between movement of the syringe plunger within the injector syringe and movement of contrast material out of the catheter and into the patient.
Due to high injection pressures, which may be on the order of 1,200 psi in some angiographic procedures, there may be an expansion of various components of the fluid delivery system, such as the syringes, tubing connected to the patient, and components of the fluid injector, such that there may be a volume of fluid in excess of the desired quantity selected for the injection procedure. Such increase in the quantity of fluid occurs due to system capacitance. Total system capacitance (also referred to as compliance or elasticity) represents the amount of fluid (i.e., excess volume) that is captured in the swelling of the components of the fluid delivery system. In general, capacitance is directly correlative to injection pressure and inversely correlative to volume of contrast medium and saline in the syringes. In other words, capacitance increases with an increase in injection pressure and an increase in pressurized volume of fluid in the syringes. Total system capacitance is inherent to each fluid delivery system and depends on a plurality of factors beyond pressure and volume of fluid remaining in the system, including, without limitation, injector construction, mechanical properties of materials used to construct the syringe, plunger, pressure jacket surrounding the syringe, fluid lines delivering the fluid to the patient, size of the syringe, plunger, pressure jacket, and fluid properties, such as temperature, viscosity, and density.
Injection rate or delivered volume can also be affected by a manner in which the syringes or reservoirs are restrained in the fluid injector. For example, tolerances are included at the interface between a disposable syringe and the injector to allow the user to connect the disposable syringe without excessive force and to prevent the disposable syringe from being damaged during attachment. While these tolerances are included for usability and manufacturing feasibility, the presence of such tolerances allows the syringe(s) to move as the drive member or the piston drives fluid through the syringe. In some cases, translation or movement of the syringe results in under delivered volume as piston motion, which causes movement of the disposable syringe does not result in delivered fluid.
Various examples of the present disclosure describe methods and fluid delivery systems comprising a fluid injector such as described herein, including dynamic pressure control, including pressure control or equalization between fluid in two or more reservoirs, in a fluid delivery system during a multiphase/multi-fluid injection includes providing a multiphase fluid delivery system having at least a first fluid reservoir configured for containing a first fluid, at least a second fluid reservoir configured for containing a second fluid, a fluid conduit for conducting fluid from the first reservoir and the second reservoir to a patient, and an injector having at least a first drive member for expelling fluid from the first reservoir and at least a second drive member for expelling fluid from the second reservoir. In various embodiments, the fluid injector system may comprise at least a third fluid reservoir in selectable fluid communication with the conduit and operatively engaged with at least one third drive member of the fluid injector for expelling at least a third fluid into the conduit. Other embodiments may further include additional fluid reservoirs.
The fluid injector and corresponding fluid reservoirs and drive members may independently be designed as a syringe (as described herein), a compressible bag with a clam-shell or other compression drive member, and a peristaltic pump with rotational drive member. For example, in certain embodiments at least one of the first fluid reservoir, the second fluid reservoir, and/or the third fluid reservoir may be a syringe, for example a front loading syringe or rolling diaphragm syringe, operatively connected to a drive member such as a piston attached to a syringe plunger or the proximal end wall of a rolling diaphragm. In specific embodiments, each of the first reservoir, the at least the second reservoir, the at least the third reservoir and any other reservoir may be a syringe operatively connected to a drive member.
According to various embodiments, each reservoir, such as the first reservoir, the at least the second reservoir, the at least the third reservoir, etc., may be independently in selective fluid communication with the conduit by a respective first valve, second valve, third valve, etc. that controls whether the system is in fluid communication or in fluid isolation with the conduit. According to certain embodiments, each of the respective valves may comprise a first, fill position wherein the fluid reservoir is in fluid communication with a fluid container but in fluid isolation with the conduit, such that proximal movement of the drive member, in the case of a syringe, draws fluid into the fluid reservoir from the fluid container. According to various embodiments, each of the respective valves may comprise a second, closed position where the fluid reservoir is fluidly isolated from at least the conduit and in specific embodiments also from the fluid container, such that the fluid reservoir is a closed system. Each of the respective valves may comprise a third, delivery position where the fluid reservoir is in fluid communication with the conduit but in fluid isolation with the fluid container, such that the fluid reservoir is an open system. Each of the respective valves may be independently controlled by the processor or controller of the fluid delivery system so that during a programmed fluid injection protocol, the valves are operated to control fluid flow of the first fluid, the second fluid, and where appropriate, the third fluid. Control of the fluid valves, in combination with advancing the corresponding drive members allows the fluid delivery system to control flow of medical fluids.
Various embodiments of the present disclosure provide methods for dynamic pressure and fluid flow control. In certain embodiments, the method comprises advancing the first drive member to expel the first fluid from the first reservoir into the conduit during a first injection phase, wherein the first fluid is pressurized to a first fluid pressure. The method then includes measuring the first fluid pressure during the first injection phase to provide a target value, wherein the target value is based at least on the measured fluid pressure of the first fluid phase. After the target value is determined and while the second reservoir is in fluid isolation from the conduit, the method includes advancing the second drive member to increase the fluid pressure of the second fluid in the second reservoir to the target value. The method then includes placing the second reservoir in fluid communication with the conduit and advancing the second drive member to expel the second fluid from the second reservoir into the conduit at a pressure equal to the target value.
According to various embodiments, the target value may be substantially equal to the first fluid pressure. As used herein, the term “substantially equal” means to within 10% of the reference value, for example from 90% to 110% of the target value. When the target value is substantially equal to the first fluid pressure, pressure equalization between the first fluid reservoir and the second fluid reservoir is obtained. In fluid injection systems that are open, i.e., no valving to isolate any of the fluid reservoirs, the fluid reservoirs are in fluid communication with each other and pressure equalization is observed, for example, pressurization of the first fluid reservoir results in pressurization of the second fluid reservoir since the fluid path provides fluid communication between the syringe reservoirs. This can have the disadvantage of a volume of the first pressurized fluid flowing into the second reservoir as the first fluid is pressurized, resulting in a mixture of the fluids in the second reservoir and in certain embodiments, increasing the time to reach the desired fluid flow rate. The reverse can occur when the second reservoir is pressurized greater than the first fluid reservoir. The mixture of fluids in a reservoir that results from this “backflow” of fluid from one reservoir to another may result in inaccuracies in the volumes of fluid delivered. According to embodiments, pressurization of the second fluid reservoir advancing the second drive member during pressurization of the first fluid reservoir by advancing the first drive member can minimize the backflow of the first fluid into the second fluid reservoir. In certain embodiments, the second drive member may be advanced at a rate equal to the rate of advancement of the first drive member so that the pressures in each reservoir are similar. Alternatively, the second drive member may be advanced at a rate less than the rate of advancement of the first drive member but at a sufficiently fast rate to minimize backflow mixing of the first fluid into the second reservoir. The rates of advancement of the second drive member relative to the rate of advancement of the first drive member may be determined by factors such as fluid types, differences in fluid viscosities, desired injection flow rates, conduit diameter including fluid line and catheter, use of dual flow protocols, dual flow ratios of fluids, system capacitance, system slack, length of fluid path, volume of fluid path, and the like. In closed systems, backflow concerns may be minimized due to the ability of the fluid injector to isolate other fluid reservoirs, for example by a controllable valve, can substantially minimize backflow of a pressurized fluid into a second fluid reservoir. According to various embodiments, with a closed fluid reservoir allows pressurization of the fluid within the fluid reservoir to substantially eliminate backflow of other pressurized fluid within the conduit when the fluid reservoir is placed in fluid communication with the conduit.
In other embodiments including a closed system, the target value may be greater than the first fluid pressure. According to these embodiments, pressurization of the second reservoir to a target value greater than the first fluid pressure may rapidly initiate the injection of the second fluid when the second reservoir is placed in fluid communication with the conduit, such that the fluid flow is kickstarted and/or prevents backflow into the second reservoir, which can lead to sharper boluses. Further, such higher target values may minimize effects of system compliance, for example, a portion of the pressure force of the first fluid swelling system components of the second reservoir.
In other embodiments, the target value may be less than the first fluid pressure. According to these embodiments, pressurization of the second reservoir to a target value less than the first fluid pressure may provide desired backflow prevention of the second fluid into the first reservoir and/or prevent over pressurization of the system. In other embodiments, the difference between the target value for the second fluid pressure relative to the first fluid pressure may be selected to provide an appropriate fluid flow ratio for a dual flow injection protocol or may more readily allow ramping to the desired dual flow ratio.
The target value may be determined by a processor associated with the fluid injector based on the specific fluid injection parameters and protocol, for example by calculation of the target value based on various factors, such as desired flow rates of the first fluid and second fluid, fluid types (e.g., contrast versus saline), system capacitance, whether dual flow injection is desired, whether backflow may be an issue, among other factors.
In certain embodiments where a dual flow injection protocol is desired, i.e., where the protocol requires a specific mixture of the first fluid and the second fluid to be injected concurrently, the step of advancing the second drive member to expel the second fluid from the second reservoir may further comprise continuing to advance the first drive member to expel the first fluid from the first reservoir to provide a dual flow fluid delivery of a predetermined ratio of the first fluid and the second fluid. The predetermined ratio may be a specified ratio ranging from 1:99 of the first fluid to the second fluid to 99:1 of the first fluid to the second fluid that may be pre-programmed into the processor by a user for a certain injection protocol or may be a predetermined or standard injection protocol that is provided by the manufacturer of the injector to provide the desired injection pattern.
In other embodiments, the method may further comprise isolating the first reservoir from fluid communication with the conduit prior to placing the second fluid reservoir in fluid communication with the conduit or, alternatively, prior to advancing the second drive member to expel the second fluid from the second reservoir in to the conduit. According to these embodiments, the injection protocol may include transitioning the injection from the first fluid to the second fluid while avoiding increases and/or fluctuations in fluid flow during the transition, for example when there is a difference in viscosity between the first fluid and the second fluid (such as a contrast media which can range from 2.0 to 30.0 cP (at 20° C.), to a lower viscosity fluid, such as saline having a viscosity of 1.0 to 1.5 cP (at 20° C.)), or avoiding backflow of the second fluid into the first fluid reservoir, or vice versa.
In other embodiments, the present disclosure provides a fluid delivery system configured for dynamic pressure control during a multiphase/multi-fluid injection, where the fluid delivery system comprises: at least a first reservoir configured for containing a first fluid; at least a second reservoir configured for containing a second fluid; a conduit connected to the first reservoir and the second reservoir for conducting fluid from the reservoirs to a patient; a fluid injector having at least a first drive member for expelling fluid from the first reservoir and at least a second drive member for expelling fluid from the second reservoir; and a controller in electronic communication with the fluid injector including computer readable memory. The controller may be associated with the fluid injector, a stand-alone operating computer, a removable operating storage media, a hospital information network, or outside computer. The memory includes instructions that when executed by the controller cause the controller to: instruct the injector to advance the first drive member to expel the first fluid from the first reservoir during a first injection phase, wherein the first fluid is pressurized to a first fluid pressure; measure the first fluid pressure during the first injection phase to provide a target value, wherein the target value is based on the measured fluid pressure of the first fluid phase; while the second reservoir is in fluid isolation from the conduit, instruct the injector to advance the second drive member to increase the fluid pressure of the second fluid in the second reservoir to the target value; instruct the injector to place the second reservoir in fluid communication with the conduit; and instruct the injector to advance the second drive member to expel the second fluid from the second reservoir into the conduit at a pressure equal to the target value.
Advantages of the various fluid pressure control methods according to various embodiments described herein include the ability to maintain flow rate across phase transitions. For example, this can maintain iodine flux across the phase transition which increases image enhancement relative to the same injection with a transient drop in flow rate. Therefore the pressure equalization is optimal use of a given contrast volume and flush, contrast volume and dual flow, contrast volume and subsequent contrast, etc. The pressure control methods may further provide a means to prevent backflow. By developing pressure in a subsequent phase reservoir, fluid from the first phase does enter the subsequent phase reservoir. By preventing backflow, bolus sharpness is improved relative to scenarios in which backflow mixing occurs. Further, pressure control methods, according to embodiments described herein, can be used to reduce over rate for scenarios in which a single reservoir is used across multiple phases during an injection to deliver fluid. For example if a reservoir delivers fluid at 200 psi during a phase and is subsequently closed by closing the valve, the 200 psi is trapped in the reservoir, for example as pressurized fluid and system capacitance. If the reservoir is used again during an injection, then the 200 psi of trapped pressure may be greater than the pressure of the intermediate phase leading to a fluctuation in fluid flow. Therefore, control of the pre-pressure can be used to reduce the trapped pressure, for example by appropriate advancement or retraction of the drive member, so that it is the same as the injection line pressure of the immediately preceding phase. Pressure control may also be used to remove system slack, for example mechanical slack and system compliance, generated by previous injection phases thereby maintaining volume accuracy across multiphase injections.
Referring to the drawings in which like reference characters refer to like parts throughout the several views thereof, the present disclosure is generally directed to fluid injector system and method for dynamic pressure control in a fluid injector. Associated disclosure related to capacitance development and issues associated with fluid injection system is described in PCT International Application No. PCT/US2017/020637, filed 3 Mar. 2017, the disclosure of which is incorporated herein by this reference.
With reference to
A conduit, such as a fluid path set 17, may be in fluid communication with each syringe 12 to place each syringe in fluid communication with a catheter for delivering the fluid F from each syringes 12 to a catheter (not shown) inserted into a patient at a vascular access site. In certain embodiments, fluid flow from the one or more syringes 12 may be regulated by a fluid control module (not shown) that operates various drive members, valves, stopcocks, and flow regulating structures to regulate the delivery of the saline solution and contrast to the patient based on user selected injection parameters, such as injection flow rate, duration, total injection volume, and ratio of fluids from the syringes 12, including specific ratios of each fluid in a dual flow injection protocol.
With reference to
Examples of suitable front-loading fluid injectors 10 are disclosed in U.S. Pat. Nos. 5,383,858; 7,553,294; 7,666,169; 9,173,995; 9,199,033; and 9,474,857; and in PCT Application Publication No. WO 2016/191485 and WO 2016/112163, the disclosures of which are incorporated by reference in their entirety.
Having described the general structure and function of specific embodiments of the fluid injector 10, an embodiment of syringe 12 configured for use with the injector 10 will now be described with reference to
In some examples, the proximal end 20 of the syringe 12 can be sized and adapted for being removably inserted in a syringe port 13 of the injector 10 (shown in
In some examples, such as shown in
With reference to
With continued reference to
The end wall 46 may have a central portion 50 having a substantially dome-shaped structure and a drive member engagement portion 52 extending proximally from the central portion 50. The drive member engagement portion 52 is configured for releasably interacting with a corresponding engagement mechanism on the drive member/piston 19 of the fluid injector 10, for example as the drive member/piston is retracted. The rolling diaphragm syringe 34 may be made of any suitable medical-grade plastic or polymeric material, desirably a clear or substantially translucent plastic material. The material of the rolling diaphragm syringe 34 is desirably selected to meet the required tensile and planar stress requirements, water vapor transmission, and chemical/biological compatibility.
With reference to
The MUDS 56 may comprise one or more syringes or pumps 58a-58c. In some aspects, the number of syringes 58 corresponds to the number of drive members/pistons on the fluid injector 10. In some examples, such as shown in
With reference to
In various embodiments, for fluid injector 10, for example any of the fluid injectors shown in
According to one example of the present disclosure, the fluid injector 10 discussed above with respect to
The first fluid F1 of the first syringe 58b and the second fluid F2 of the second syringe 58a may be different fluids, such as medical fluids having different properties, such as different viscosities. Alternatively the first fluid F1 and the second fluid F2 may be the same fluid, for example medical fluid but at different concentrations or temperatures, or the same fluid being delivered at a different flow rate. For example, the first and second fluids F1, F2 may have one or more of a different viscosity, temperature, and/or density. In one example of the present disclosure, the first fluid F1 may be contrast media, as described herein, having a first viscosity and the second fluid F2 may be saline having a second viscosity which is typically lower than the first viscosity. In certain embodiments, the fluid injector may have a third syringe 58c, which may contain a third fluid F3 that may be the same or different that the first fluid F1 and second fluid F2. For example, F3 may be a contrast media, which may be the same as first fluid F1 or F3 may be a different contrast agent than F1, or F3 may be the same contrast type as F1 but at a different concentration than F1. During the first phase of the multi-phase injection, the first fluid F1, i.e. contrast, may be injected from the first syringe 58b at a first predetermined flow rate programmed into the injector 10. Delivery of the first fluid F1 at the first predetermined flow rate is achieved by applying a pressure to the first fluid F1 in the first syringe 58b, such as by driving the plunger of the first syringe 58b with the piston 19, where the necessary applied pressure to achieve the desired first predetermined flow rate is a function of the first viscosity of the first fluid F1. Because of the generally higher viscosity of the contrast of the first fluid F1, higher applied pressures are generally required to achieve a predetermined flow rate compared to the necessary applied pressure to achieve the same flow rate for a fluid with a lower viscosity, such as saline. Following the first phase of the multi-phase injection, the second phase includes injection of the second fluid F2, i.e. saline, from the second syringe 58a. The second predetermined flow rate of the second fluid F2 may be the same as, greater than, or lower than the first predetermined flow rate of the first fluid F1. In fluid injections where the first and second predetermined flow rates are targeted to be the same, due to the differences between the first viscosity of the first fluid F1 and the second viscosity of the second fluid F2, the pressure required to deliver the second fluid F2 may differ from the pressure required to deliver the first fluid F1. In the present example, the pressure applied to the first fluid F1, i.e. contrast media, is generally higher than the pressure applied to the second fluid F2, i.e. saline, in order to obtain the same flow rate. In other examples, the second predetermined flow rate of the second fluid F2 may be different than the first predetermined flow rate of the first fluid F1, yet the pressures necessary to achieve the predetermined flow rates of the first fluid F1 and the second fluid F2 may still be different.
A schematic drawing of a fluid delivery system 102 similar to the systems 10 shown in
In some examples, the system 102 also includes a fluid injector 110 configured to receive the syringes 112, 114, or MUDS 56. The syringes 112, 114 can be front loading syringes having a movable plunger for expelling fluid therefrom, rolling diaphragm syringes as previously described, or other types of disposable or reusable syringes as are known in the art. The injector 110 can be similar to the front loading injector 10 (shown in
In some examples, the system 102 further includes a fluid control device, such as valves 178, 180 for restricting fluid flow between the syringes 112, 114 and conduit 117. Valves for regulating fluid flow through the system 102 can include, for example, stopcocks, check valves, ball valves, diaphragm valves, and other types of manually or automatically actuatable valves, as are known in the art. In some examples, valves for different syringes can be combined into a single manifold device, such as the manifold 70, shown in
In some examples, the system 102 further comprises sensors 106, 108 associated with the first syringe 112 and/or the second syringe 114 or with the fluid path associated with each syringe. Various different types of sensors can be used for measuring information about syringe type, fluids F1, F2 contained in the syringes 112, 114, injection parameters for an injection being performed, or environmental conditions (e.g., ambient temperature) near the injector 110. In some examples, the sensors 106, 108 can be fluid pressure transducers, pressure gauges, strain gauges, or sensors configured to measure fluid pressure in the syringes 112, 114 or conduit 117. Syringe pressure can also be measured by monitoring motor current of the injector 110 to determine force required for driving the plunger through the syringe barrel. According to various embodiments, pressure control can be used to eliminate slack that develops during an injection. As an example, the syringe(s) may display compliance or impedance under pressurization, such as where the syringe stretches axially, injector/syringe interfaces deflect and/or displace, or the restraints bend. This causes slack as the piston can move away from the plunger on a non-injecting reservoir/syringe. A schematic representation of a fluid delivery system 102 illustrating slack due to deflection of syringe components during an injection is shown in
In some examples, the system 102 further includes a controller 104 in electrical communication with the injector 110, valves 178, 180, sensors 106, 108, and other components of the system 102. The controller 104 is generally configured to control an injection process by actuating the drive member(s) of the injector 110 to control fluid delivery. The controller 104 can also be configured to record information about an injection procedure and, in some instances, to control transmission of recorded information to remote sources through a transceiver or communications device associated with the controller 104, as are known in the art. The controller 104 can be a computer processor or processing device associated with computer readable memory for operating components of the fluid delivery system 102. In some examples, the controller 104 is an electronic component of the injector 110 contained within the injector housing. In that case, the controller 104 can be configured to control or manage other electrical components of the injector 110, such as a visual display, control panel, user input device, and others. In other examples, the controller 104 can be a separate electronic device, such as a computer tablet, smart phone, or personal computer, in electrical communication with the injector 110. In that case, the controller 104 can be configured to receive information and instructions from the injector 110, sensors 106, 108, or valves 178, 180, process the received information, and transmit instructions to components of the system 102 based on the processing information. In some examples, as described in connection with
With reference to
In some examples, the method includes providing a multiphase fluid delivery system as shown at step 210. The multiphase fluid delivery system can include components of the systems, injectors, and syringes shown in
As shown at step 212, the process includes advancing the first drive member to expel fluid from the first reservoir into the conduit during a first injection phase. For example, a user may actuate the first drive mechanism by pressing an appropriate button or control dial on the injector to cause a piston or linear actuator to advance towards a plunger of the syringe, engage the plunger, and advance the plunger through the syringe to expel fluid therefrom. As shown at step 214, a fluid pressure of the injection is measured during the first injection phase. Fluid pressure can be measured by a pressure transducer or strain gauge positioned in a barrel of the syringe or in a portion of the conduit or fluid path set. In other examples, fluid pressure can be measured indirectly, such as by measuring fluid flow rate through the syringe and/or conduit and determining pressure based on fluid density. In other examples, pressure can be determined based on motor current drawn by the injector. In some examples, fluid pressure is measured continually during an entire first injection phase, as occurs, for example, when using an analog gas gauge. In other examples, fluid pressure can be measured periodically, such as at predetermined intervals during the first injection phase.
During the first injection phase, in one embodiment, as shown at step 216, the system may be configured to ensure that the valve connected to or associated with the second syringe is in a closed position and/or that the second syringe is not in fluid communication with the conduit, so that the second reservoir can be pressurized by movement of the piston and plunger. In other examples, the valve does not need to be closed. In that case, the piston can move forward to generate a matching pressure (e.g., a pressure which matches the first phase pressure). However, leaving the valve open may result in fluid mixing depending on fluid properties and orientation of fluid, among other factors. In other examples, in order to reduce or eliminate mixing, a valve, such as a stopcock, can be partially opened to some small opening size and the piston can be moved forward to generate the desired pressure. In other examples, pinch valves, roller valves, or clamps can be used in place of a stopcock.
In another embodiment, while the second reservoir or syringe is not in fluid communication with the conduit, as shown at step 218, the second drive member is advanced through the second reservoir to increase fluid pressure in the second reservoir. The drive member continues to advance until fluid pressure in the second reservoir increases to a target value determined based on the measured fluid pressure during the first injection phase. In some examples, the target value is equal to the previously measured fluid pressure during the first injection phase. In other examples, the target value can be a percentage of the previously measured pressure value. For example, the target value can be between about 0% and 200% of the previously measured fluid pressure. For instance, if the measured injection pressure is 100 psi and the target is about 80%, then the second reservoir piston will move until the pressure is 80 psi.
In some examples, fluid pressure in the second reservoir or syringe may be measured using an electronic pressure transducer or sensor in fluid communication with the reservoir. In that case, a system controller can be configured to continue to advance the drive member of the injector until a measurement by the sensor confirms that the target pressure has been obtained. When the target pressure is obtained, the controller can be configured to provide an instruction to the injector to cause the injector to stop advancing the drive member. In other examples, a final position of the drive member and/or syringe plunger can be calculated based on the measured fluid pressure during the first injection phase and a present position of the drive member. For example, the controller can be configured to obtain information about a position of the drive member and desired final fluid pressure. The controller can calculate how far the plunger must be advanced to obtain the target pressure. In other examples, if the first fluid injecting pressure decreases, the drive piston can move backwards/retract, for example at a constant rate or a stepped rate, to reduce the pressure in accordance with the target pressure. The controller can then cause the drive mechanism to advance the plunger the calculated distance. In this way, the controller can cause the syringe pressure of the second syringe to increase without needing to continuously or periodically measure fluid pressure of the second syringe. In various embodiments, measurement of the pressure of the second fluid in the second reservoir may not be needed during this process.
Once the target fluid pressure in the second syringe is obtained, the fluid delivery system is ready to begin delivery of the second fluid or contrast to the patient (e.g., the second injection phase). Factors other than pressure may also be relevant for determining when to begin the second injection phase. However, in most examples, the second injection phase should only start once the target pressure is reached. In order to perform the second injection phase, as shown at 220, the valve is manually or automatically opened to establish fluid communication between an interior of the second reservoir and the fluid conduit or fluid path set. Once the valve is opened, the drive member can continue to advance to expel fluid from the second reservoir and to the conduit as shown at step 222. Optionally, the valve for the first syringe may be closed to isolate the first syringe from the fluid path or, alternatively, partially closed to allow pressure control between the syringes while minimizing mixing of the second fluid with the first fluid in the first syringe.
For example according to a non-limiting example of a 3-phase injection protocol, such as a contrast—saline—contrast injection protocol, the first contrast phase may generate a pressure of 100 psi, which the second saline phase may generate a pressure of 20 psi. When transitioning from contrast to saline, the 100 psi of the contrast pressure is trapped in the contrast reservoir after the contrast reservoir is fluidly isolated with a valve, and the saline phase starts at 100 psi, due to matching the pressure in the fluid line, and then falls to 20 psi. During the saline phase injection, the trapped pressure in the contrast reservoir must be lowered to the pressure of the saline, i.e., 20 psi, so that at the start of the third phase (second contrast phase) the pressure of the contrast in the third phase matches the 20 psi system pressure from the saline phase, thereby eliminating flow rate fluctuations and potential backflow of contrast into the saline reservoir. At the end of the injection protocol, all reservoirs may be fluidly isolated by the corresponding valves and the pressure within each reservoir returned to 0 psi to prepare the system for the next injection protocol.
A pressure control process, as described herein, provides several benefits for a multiphase injector system compared to processes without pressure control. For example, driving the second drive member or piston forward to increase pressure of the second fluid reservoir or syringe ensures that the plunger of the second syringe remains in contact with the fluid for any subsequent phase. Further, driving the plunger of the second syringe forward eliminates slack introduced into the system due to movement of the disposable syringes during a previous injection phase, thereby improving volume accuracy and eliminating decreases in flow rate at the phase transition.
Pressurizing a subsequent injection phase, such as the saline or second phase of an injection process, also removes a compliance of the isolated second reservoir. Removing compliance of the second reservoir ensures that all piston movement during the subsequent phase results in fluid delivery rather than expansion of the system. This also minimizes or eliminates any dip in flow rate when transitioning from one injection phase to another, as shown by the graphs in
In some examples, the pressure control process described herein can also be adapted for use with a single syringe. In other examples, injection systems having more than two syringes and for injection processes including a dual flow phase. Beneficially, the pressure control process improves dual flow ratio accuracy since fluid is delivered from pressurized reservoirs during the entire dual flow phase. In contrast, when pressure control is not performed, a portion of the phase is spent taking up system compliance.
In some examples, pressure control can be performed for the first phase of an injection or with a single syringe injection. The target pressure can be a set value (for example 100 psi) or can be determined based on the compliance of the system. Beneficially, pre-pressurizing the first injection phase would remove the ramp time required to reach the desired flow rate. Pre-pressurizing the first injection phase would also result in a sharper bolus. See
According to other aspects, the pressure control process prevents cross contamination between fluid reservoirs, which provides a sharper bolus/transition as the concentration of contrast or saline remains pure in the respective reservoir. Avoiding cross-contamination between fluid reservoirs is important for multi-patient systems in which cross-contamination of fluid reservoirs would accumulate throughout the use life of the system.
Graphs showing injection parameters for injections performed using the above described process are shown in
Although the disclosure has been described in detail for the purpose of illustration based on what is currently considered to be the most practical and preferred examples, it is to be understood that such detail is solely for that purpose and that the disclosure is not limited to the disclosed examples, but, on the contrary, is intended to cover modifications and equivalent arrangements. For example, it is to be understood that the present disclosure contemplates that, to the extent possible, one or more features of any example can be combined with one or more features of any other example.
This application is a U.S. national phase application under 35 U.S.C. § 371 of PCT International Application No. PCT/US2018/048283, filed 28 Aug. 2018 and claims priority to U.S. Provisional Application No. 62/552,433, titled “System and Method for Dynamic Pressure Equalization in a Fluid Injector System” and filed on 31 Aug. 2017, the disclosures of which are incorporated herein in their entirety.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2018/048283 | 8/28/2018 | WO |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2019/046260 | 3/7/2019 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
383858 | Campbell | Jun 1888 | A |
508584 | Stevens | Nov 1893 | A |
945143 | Iacques | Jan 1910 | A |
2511291 | Mueller | Jun 1950 | A |
2583206 | Borck et al. | Jan 1952 | A |
3156236 | Williamson | Nov 1964 | A |
3159312 | Van Sciver, II | Dec 1964 | A |
3276472 | Jinkens et al. | Oct 1966 | A |
3349713 | Fassbender | Oct 1967 | A |
3520295 | Kelly | Jul 1970 | A |
3523523 | Heinrich et al. | Aug 1970 | A |
3623474 | Heilman | Nov 1971 | A |
3635444 | Potter | Jan 1972 | A |
3671208 | Wayne | Jun 1972 | A |
3701345 | Heilman | Oct 1972 | A |
3719207 | Takeda | Mar 1973 | A |
3755655 | Senecal | Aug 1973 | A |
3793600 | Grosbard | Feb 1974 | A |
3812843 | Wootten et al. | May 1974 | A |
3817843 | Barrett | Jun 1974 | A |
3839708 | Lyons et al. | Oct 1974 | A |
3868967 | Harding | Mar 1975 | A |
3888239 | Rubinstein | Jun 1975 | A |
3895220 | Nelson et al. | Jul 1975 | A |
3898983 | Elam | Aug 1975 | A |
3927955 | Spinosa et al. | Dec 1975 | A |
3941126 | Dietrich et al. | Mar 1976 | A |
3958103 | Oka et al. | May 1976 | A |
3968195 | Bishop | Jul 1976 | A |
3995381 | Manfred et al. | Dec 1976 | A |
4001549 | Corwin | Jan 1977 | A |
4006736 | Kranys et al. | Feb 1977 | A |
4038981 | Lefevre et al. | Aug 1977 | A |
4044757 | Mcwhorter et al. | Aug 1977 | A |
4090502 | Tajika | May 1978 | A |
4135247 | Gordon et al. | Jan 1979 | A |
4151845 | Clemens | May 1979 | A |
4187057 | Xanthopoulos | Feb 1980 | A |
4191183 | Mendelson | Mar 1980 | A |
4199000 | Edstrom | Apr 1980 | A |
4204775 | Speer | May 1980 | A |
4207871 | Jenkins | Jun 1980 | A |
4208136 | King et al. | Jun 1980 | A |
4223675 | Williams | Sep 1980 | A |
4262824 | Hrynewycz | Apr 1981 | A |
4263916 | Brooks et al. | Apr 1981 | A |
4280494 | Cosgrove, Jr. et al. | Jul 1981 | A |
4284073 | Krause et al. | Aug 1981 | A |
4315247 | Germanton | Feb 1982 | A |
4319568 | Tregoning | Mar 1982 | A |
4329067 | Goudy, Jr. | May 1982 | A |
4340153 | Spivey | Jul 1982 | A |
4341153 | Bowser | Jul 1982 | A |
4392847 | Whitney et al. | Jul 1983 | A |
4392849 | Petre et al. | Jul 1983 | A |
4396385 | Kelly et al. | Aug 1983 | A |
4402310 | Kimura | Sep 1983 | A |
4409966 | Lambrecht et al. | Oct 1983 | A |
4434820 | Glass | Mar 1984 | A |
4434822 | Bellamy et al. | Mar 1984 | A |
4441823 | Power et al. | Apr 1984 | A |
4444198 | Petre | Apr 1984 | A |
4447230 | Gula et al. | May 1984 | A |
4448200 | Brooks et al. | May 1984 | A |
4474476 | Thomsen | Oct 1984 | A |
4477923 | Baumann et al. | Oct 1984 | A |
4479760 | Bilstad et al. | Oct 1984 | A |
4479761 | Bilstad et al. | Oct 1984 | A |
4479762 | Bilstad et al. | Oct 1984 | A |
4504908 | Riederer et al. | Mar 1985 | A |
4509526 | Barnes et al. | Apr 1985 | A |
4512764 | Wunsch | Apr 1985 | A |
4542459 | Riederer | Sep 1985 | A |
4544949 | Kurihara | Oct 1985 | A |
4551133 | Zegers et al. | Nov 1985 | A |
4552130 | Kinoshita | Nov 1985 | A |
4559036 | Wunsch | Dec 1985 | A |
4563175 | Lafond | Jan 1986 | A |
4578802 | Itoh | Mar 1986 | A |
4585009 | Barker et al. | Apr 1986 | A |
4585941 | Bergner | Apr 1986 | A |
4610670 | Spencer | Sep 1986 | A |
4610790 | Reti et al. | Sep 1986 | A |
4611340 | Okazaki | Sep 1986 | A |
4612572 | Komatsu et al. | Sep 1986 | A |
4625494 | Iwatschenko et al. | Dec 1986 | A |
4626144 | Berner | Dec 1986 | A |
4633307 | Honda | Dec 1986 | A |
4634426 | Kamen | Jan 1987 | A |
4636144 | Abe et al. | Jan 1987 | A |
4655197 | Atkinson | Apr 1987 | A |
4662906 | Matkovich et al. | May 1987 | A |
4672651 | Horiba et al. | Jun 1987 | A |
4676776 | Howson | Jun 1987 | A |
4682170 | Kubota et al. | Jul 1987 | A |
4689670 | Okazaki | Aug 1987 | A |
4710166 | Thompson et al. | Dec 1987 | A |
4723261 | Janssen et al. | Feb 1988 | A |
4750643 | Wortrich | Jun 1988 | A |
4754786 | Roberts | Jul 1988 | A |
4781687 | Wall | Nov 1988 | A |
4783273 | Knutsson et al. | Nov 1988 | A |
4789014 | Digianfilippo et al. | Dec 1988 | A |
4793357 | Lindstrom | Dec 1988 | A |
4795429 | Feldstein | Jan 1989 | A |
4798590 | O'Leary et al. | Jan 1989 | A |
4804454 | Asakura et al. | Feb 1989 | A |
4823833 | Hogan et al. | Apr 1989 | A |
4835521 | Andrejasich et al. | May 1989 | A |
4836187 | Iwakoshi et al. | Jun 1989 | A |
4838856 | Mulreany et al. | Jun 1989 | A |
4840620 | Kobayashi et al. | Jun 1989 | A |
4844052 | Iwakoshi et al. | Jul 1989 | A |
4853521 | Claeys et al. | Aug 1989 | A |
4854301 | Nakajima | Aug 1989 | A |
4854324 | Hirschman et al. | Aug 1989 | A |
4857056 | Talonn | Aug 1989 | A |
4874359 | White et al. | Oct 1989 | A |
4879880 | Harrison | Nov 1989 | A |
4880014 | Zarowitz et al. | Nov 1989 | A |
4887208 | Schneider et al. | Dec 1989 | A |
4887554 | Whitford | Dec 1989 | A |
4901731 | Millar | Feb 1990 | A |
4903705 | Imamura et al. | Feb 1990 | A |
4913154 | Ermert et al. | Apr 1990 | A |
4922916 | Ermert et al. | May 1990 | A |
4925444 | Orkin et al. | May 1990 | A |
4929818 | Bradbury et al. | May 1990 | A |
4935005 | Haines | Jun 1990 | A |
4936832 | Vaillancourt | Jun 1990 | A |
4943279 | Samiotes et al. | Jul 1990 | A |
4943779 | Pedersen et al. | Jul 1990 | A |
4943987 | Asahina et al. | Jul 1990 | A |
4946256 | Woodruff | Aug 1990 | A |
4946439 | Eggers | Aug 1990 | A |
4947412 | Mattson | Aug 1990 | A |
4950245 | Brown et al. | Aug 1990 | A |
4952068 | Flint | Aug 1990 | A |
4954129 | Giuliani et al. | Sep 1990 | A |
4965726 | Heuscher et al. | Oct 1990 | A |
4966579 | Polaschegg | Oct 1990 | A |
4976687 | Martin | Dec 1990 | A |
4978335 | Arthur, III | Dec 1990 | A |
4981467 | Bobo, Jr. et al. | Jan 1991 | A |
4995064 | Wilson et al. | Feb 1991 | A |
5002055 | Merki et al. | Mar 1991 | A |
5004472 | Wallace et al. | Apr 1991 | A |
5009654 | Minshall et al. | Apr 1991 | A |
5010473 | Jacobs | Apr 1991 | A |
5013173 | Shiraishi | May 1991 | A |
5018173 | Komai et al. | May 1991 | A |
5032112 | Fairchild et al. | Jul 1991 | A |
5034987 | Fujimoto et al. | Jul 1991 | A |
5040537 | Katakura | Aug 1991 | A |
5053002 | Barlow | Oct 1991 | A |
5054044 | Audon et al. | Oct 1991 | A |
5056568 | Digianfilippo et al. | Oct 1991 | A |
5059171 | Bridge et al. | Oct 1991 | A |
5059173 | Sacco | Oct 1991 | A |
5061243 | Winchell et al. | Oct 1991 | A |
5069662 | Bodden | Dec 1991 | A |
5078683 | Sancoff et al. | Jan 1992 | A |
5088981 | Howson et al. | Feb 1992 | A |
5100380 | Epstein et al. | Mar 1992 | A |
5104374 | Bishko et al. | Apr 1992 | A |
5104387 | Pokorney et al. | Apr 1992 | A |
5108365 | Woods, Jr. | Apr 1992 | A |
5111492 | Klausz | May 1992 | A |
5113905 | Pruitt et al. | May 1992 | A |
5123056 | Wilson | Jun 1992 | A |
5123121 | Broersma | Jun 1992 | A |
5125018 | Asahina | Jun 1992 | A |
5128121 | Berg et al. | Jul 1992 | A |
5133336 | Savitt et al. | Jul 1992 | A |
5135000 | Akselrod et al. | Aug 1992 | A |
5140862 | Pappalardo | Aug 1992 | A |
5150292 | Hoffmann et al. | Sep 1992 | A |
5166961 | Brunnett et al. | Nov 1992 | A |
5180895 | Briggs et al. | Jan 1993 | A |
5180896 | Gibby et al. | Jan 1993 | A |
5190744 | Rocklage et al. | Mar 1993 | A |
5191878 | Iida et al. | Mar 1993 | A |
5196007 | Ellman et al. | Mar 1993 | A |
5199604 | Palmer et al. | Apr 1993 | A |
5207642 | Orkin et al. | May 1993 | A |
5215095 | Macvicar et al. | Jun 1993 | A |
5228070 | Mattson | Jul 1993 | A |
5230614 | Zanger et al. | Jul 1993 | A |
5242390 | Goldrath | Sep 1993 | A |
5249122 | Stritzke | Sep 1993 | A |
5249579 | Hobbs et al. | Oct 1993 | A |
5262946 | Heuscher | Nov 1993 | A |
5267174 | Kaufman et al. | Nov 1993 | A |
5269756 | Dryden | Dec 1993 | A |
5273537 | Haskvitz et al. | Dec 1993 | A |
5274218 | Urata et al. | Dec 1993 | A |
5276614 | Heuscher | Jan 1994 | A |
5286252 | Tuttle et al. | Feb 1994 | A |
5287273 | Kupfer et al. | Feb 1994 | A |
5295967 | Rondelet et al. | Mar 1994 | A |
5300031 | Neer et al. | Apr 1994 | A |
5301656 | Negoro et al. | Apr 1994 | A |
5301672 | Kalender | Apr 1994 | A |
5304126 | Epstein et al. | Apr 1994 | A |
5310997 | Roach et al. | May 1994 | A |
5311568 | McKee, Jr. et al. | May 1994 | A |
5313992 | Grabenkort | May 1994 | A |
5317506 | Coutre et al. | May 1994 | A |
5328463 | Barton et al. | Jul 1994 | A |
5329459 | Kaufman et al. | Jul 1994 | A |
5334141 | Carr et al. | Aug 1994 | A |
5339799 | Kami et al. | Aug 1994 | A |
5349625 | Born et al. | Sep 1994 | A |
5349635 | Scott | Sep 1994 | A |
5352979 | Conturo | Oct 1994 | A |
5354273 | Hagen | Oct 1994 | A |
5361761 | Van et al. | Nov 1994 | A |
5362948 | Morimoto | Nov 1994 | A |
5368562 | Blomquist et al. | Nov 1994 | A |
5368567 | Lee | Nov 1994 | A |
5368570 | Thompson et al. | Nov 1994 | A |
5373231 | Boll et al. | Dec 1994 | A |
5376070 | Purvis et al. | Dec 1994 | A |
5378231 | Johnson et al. | Jan 1995 | A |
5382232 | Hague et al. | Jan 1995 | A |
5383231 | Yamagishi | Jan 1995 | A |
5383858 | Reilly et al. | Jan 1995 | A |
5385540 | Abbott et al. | Jan 1995 | A |
5388139 | Beland | Feb 1995 | A |
5392849 | Matsunaga et al. | Feb 1995 | A |
5400792 | Hoebel et al. | Mar 1995 | A |
5417213 | Prince | May 1995 | A |
5431627 | Pastrone et al. | Jul 1995 | A |
5433704 | Ross et al. | Jul 1995 | A |
5445621 | Poli et al. | Aug 1995 | A |
5450847 | Kaempfe et al. | Sep 1995 | A |
5453639 | Cronin et al. | Sep 1995 | A |
5456255 | Abe et al. | Oct 1995 | A |
5458128 | Polanyi et al. | Oct 1995 | A |
5459769 | Brown | Oct 1995 | A |
5460609 | O'Donnell | Oct 1995 | A |
5464391 | Devale | Nov 1995 | A |
5468240 | Gentelia et al. | Nov 1995 | A |
5469769 | Sawada et al. | Nov 1995 | A |
5469849 | Sasaki et al. | Nov 1995 | A |
5472403 | Cornacchia et al. | Dec 1995 | A |
5474683 | Bryant et al. | Dec 1995 | A |
5485831 | Holdsworth et al. | Jan 1996 | A |
5489265 | Montalvo et al. | Feb 1996 | A |
5494036 | Uber, III et al. | Feb 1996 | A |
5494822 | Sadri | Feb 1996 | A |
5496273 | Pastrone et al. | Mar 1996 | A |
5507412 | Ebert et al. | Apr 1996 | A |
5515851 | Goldstein | May 1996 | A |
5522798 | Johnson et al. | Jun 1996 | A |
5531679 | Schulman et al. | Jul 1996 | A |
5531697 | Olsen et al. | Jul 1996 | A |
5533978 | Teirstein | Jul 1996 | A |
5544215 | Shroy, Jr. et al. | Aug 1996 | A |
5547470 | Johnson et al. | Aug 1996 | A |
5552130 | Kraus et al. | Sep 1996 | A |
5553619 | Prince | Sep 1996 | A |
5560317 | Bunyan et al. | Oct 1996 | A |
5566092 | Wang et al. | Oct 1996 | A |
5569181 | Heilman et al. | Oct 1996 | A |
5569208 | Woelpper et al. | Oct 1996 | A |
5573515 | Wilson et al. | Nov 1996 | A |
5579767 | Prince | Dec 1996 | A |
5583902 | Bae | Dec 1996 | A |
5590654 | Prince | Jan 1997 | A |
5592940 | Kampfe et al. | Jan 1997 | A |
5601086 | Pretlow, III et al. | Feb 1997 | A |
5611344 | Bernstein et al. | Mar 1997 | A |
5616124 | Hague et al. | Apr 1997 | A |
5681285 | Ford et al. | Oct 1997 | A |
5687208 | Bae et al. | Nov 1997 | A |
5687708 | Farnsworth et al. | Nov 1997 | A |
5713358 | Mistretta et al. | Feb 1998 | A |
5724976 | Mine et al. | Mar 1998 | A |
5725500 | Micheler | Mar 1998 | A |
5739508 | Uber, III | Apr 1998 | A |
5743266 | Levene et al. | Apr 1998 | A |
5768405 | Makram-Ebeid | Jun 1998 | A |
5796862 | Pawlicki et al. | Aug 1998 | A |
5799649 | Prince | Sep 1998 | A |
5800397 | Wilson et al. | Sep 1998 | A |
5806519 | Evans, III et al. | Sep 1998 | A |
5808203 | Nolan, Jr. et al. | Sep 1998 | A |
5827219 | Uber, III et al. | Oct 1998 | A |
5827504 | Yan et al. | Oct 1998 | A |
5840026 | Uber, III et al. | Nov 1998 | A |
5843037 | Uber, III | Dec 1998 | A |
5846517 | Unger | Dec 1998 | A |
5865744 | Lemelson | Feb 1999 | A |
5873861 | Hitchins et al. | Feb 1999 | A |
5881124 | Giger et al. | Mar 1999 | A |
5882343 | Wilson et al. | Mar 1999 | A |
5902054 | Coudray | May 1999 | A |
5903454 | Hoffberg et al. | May 1999 | A |
5916165 | Duchon et al. | Jun 1999 | A |
5920054 | Uber, III | Jul 1999 | A |
5947935 | Kazousky et al. | Sep 1999 | A |
5987347 | Khoury et al. | Nov 1999 | A |
5988587 | Duchon et al. | Nov 1999 | A |
6046225 | Maddock | Apr 2000 | A |
6055985 | Bae et al. | May 2000 | A |
6056902 | Hettinga | May 2000 | A |
6063052 | Uber, III et al. | May 2000 | A |
6073042 | Simonetti | Jun 2000 | A |
6099502 | Duchon et al. | Aug 2000 | A |
6113568 | Olaussen | Sep 2000 | A |
6132396 | Antanavich et al. | Oct 2000 | A |
6149627 | Uber, III | Nov 2000 | A |
6186146 | Glickman | Feb 2001 | B1 |
6201889 | Vannah | Mar 2001 | B1 |
6221045 | Duchon et al. | Apr 2001 | B1 |
6236706 | Hsieh | May 2001 | B1 |
6248093 | Moberg | Jun 2001 | B1 |
6306117 | Uber, III | Oct 2001 | B1 |
6313131 | Lawyer | Nov 2001 | B1 |
6317623 | Griffiths et al. | Nov 2001 | B1 |
6322535 | Hitchins et al. | Nov 2001 | B1 |
6344030 | Duchon et al. | Feb 2002 | B1 |
6381486 | Mistretta et al. | Apr 2002 | B1 |
6387098 | Cole et al. | May 2002 | B1 |
6397093 | Aldrich | May 2002 | B1 |
6397097 | Requardt | May 2002 | B1 |
6402697 | Calkins et al. | Jun 2002 | B1 |
6423719 | Lawyer | Jul 2002 | B1 |
6442418 | Evans, III et al. | Aug 2002 | B1 |
6470889 | Bae et al. | Oct 2002 | B1 |
6471674 | Emig et al. | Oct 2002 | B1 |
6478735 | Pope et al. | Nov 2002 | B1 |
6503226 | Martinell et al. | Jan 2003 | B1 |
6520930 | Critchlow et al. | Feb 2003 | B2 |
6527718 | Connor et al. | Mar 2003 | B1 |
6554819 | Reich | Apr 2003 | B2 |
6556695 | Packer et al. | Apr 2003 | B1 |
6572851 | Muramatsu et al. | Jun 2003 | B2 |
6574496 | Golman et al. | Jun 2003 | B1 |
6575930 | Trombley, III et al. | Jun 2003 | B1 |
6597938 | Liu | Jul 2003 | B2 |
6626862 | Duchon et al. | Sep 2003 | B1 |
6635030 | Bae et al. | Oct 2003 | B1 |
6643537 | Zatezalo et al. | Nov 2003 | B1 |
6652489 | Trocki et al. | Nov 2003 | B2 |
6656157 | Duchon et al. | Dec 2003 | B1 |
6673033 | Sciulli et al. | Jan 2004 | B1 |
6685733 | Dae et al. | Feb 2004 | B1 |
6691047 | Fredericks | Feb 2004 | B1 |
6699219 | Emig et al. | Mar 2004 | B2 |
6731971 | Evans et al. | May 2004 | B2 |
6754521 | Prince | Jun 2004 | B2 |
6775764 | Batcher | Aug 2004 | B1 |
6776764 | Pinsky | Aug 2004 | B2 |
6866653 | Bae | Mar 2005 | B2 |
6876720 | Tsuyuki | Apr 2005 | B2 |
6879853 | Meaney et al. | Apr 2005 | B2 |
6983590 | Roelle et al. | Jan 2006 | B2 |
7094216 | Trombley, III et al. | Aug 2006 | B2 |
7267666 | Duchon et al. | Sep 2007 | B1 |
7267667 | Hou et al. | Sep 2007 | B2 |
7292720 | Horger et al. | Nov 2007 | B2 |
7351221 | Trombley et al. | Apr 2008 | B2 |
7553294 | Lazzaro et al. | Jun 2009 | B2 |
7553295 | Susi | Jun 2009 | B2 |
7563249 | Schriver et al. | Jul 2009 | B2 |
7666169 | Cowan et al. | Feb 2010 | B2 |
7688057 | Foss et al. | Mar 2010 | B2 |
7861893 | Voegele et al. | Jan 2011 | B2 |
7925330 | Kalafut et al. | Apr 2011 | B2 |
8007487 | Patrick et al. | Aug 2011 | B2 |
8147464 | Spohn et al. | Apr 2012 | B2 |
8162903 | Reilly et al. | Apr 2012 | B2 |
8295914 | Kalafut et al. | Oct 2012 | B2 |
8337456 | Schriver et al. | Dec 2012 | B2 |
8377003 | Wagner | Feb 2013 | B2 |
8403909 | Spohn et al. | Mar 2013 | B2 |
8439863 | Fago et al. | May 2013 | B2 |
8486017 | Masuda et al. | Jul 2013 | B2 |
8905969 | Nystrom et al. | Dec 2014 | B2 |
8945051 | Schriver et al. | Feb 2015 | B2 |
9101708 | Small et al. | Aug 2015 | B2 |
9173995 | Tucker et al. | Nov 2015 | B1 |
9199033 | Cowan et al. | Dec 2015 | B1 |
9238099 | Kalafut et al. | Jan 2016 | B2 |
9242083 | Fago et al. | Jan 2016 | B2 |
9259527 | Spohn et al. | Feb 2016 | B2 |
9314749 | Yagi et al. | Apr 2016 | B2 |
9333293 | Williams, Jr. et al. | May 2016 | B2 |
9474857 | Riley et al. | Oct 2016 | B2 |
9480791 | Reilly | Nov 2016 | B2 |
9555379 | Schriver et al. | Jan 2017 | B2 |
9901671 | Toews et al. | Feb 2018 | B2 |
9987413 | Seibold et al. | Jun 2018 | B2 |
10041483 | Chappel et al. | Aug 2018 | B2 |
10112008 | Neftel et al. | Oct 2018 | B2 |
10201666 | Cowan et al. | Feb 2019 | B2 |
10391234 | Sams et al. | Aug 2019 | B2 |
10549084 | Sokolov et al. | Feb 2020 | B2 |
10583256 | Berry et al. | Mar 2020 | B2 |
20010018937 | Nemoto | Sep 2001 | A1 |
20010027265 | Prince | Oct 2001 | A1 |
20010056233 | Uber et al. | Dec 2001 | A1 |
20020007116 | Zatezalo et al. | Jan 2002 | A1 |
20020010551 | Wang et al. | Jan 2002 | A1 |
20020026148 | Uber et al. | Feb 2002 | A1 |
20020099254 | Movahed | Jul 2002 | A1 |
20020123702 | Cho | Sep 2002 | A1 |
20020151854 | Duchon et al. | Oct 2002 | A1 |
20030050556 | Uber et al. | Mar 2003 | A1 |
20030120171 | Diamantopoulos et al. | Jun 2003 | A1 |
20030195462 | Mann et al. | Oct 2003 | A1 |
20030212364 | Mann et al. | Nov 2003 | A1 |
20030216683 | Shekalim | Nov 2003 | A1 |
20030226539 | Kim et al. | Dec 2003 | A1 |
20040011740 | Bernard et al. | Jan 2004 | A1 |
20040025452 | Mclean | Feb 2004 | A1 |
20040044302 | Bernard et al. | Mar 2004 | A1 |
20040064041 | Lazzaro et al. | Apr 2004 | A1 |
20040092905 | Azzolini | May 2004 | A1 |
20040097806 | Hunter et al. | May 2004 | A1 |
20040154788 | Symonds | Aug 2004 | A1 |
20040162484 | Nemoto | Aug 2004 | A1 |
20040163655 | Gelfand et al. | Aug 2004 | A1 |
20040167415 | Gelfand et al. | Aug 2004 | A1 |
20040215144 | Duchon et al. | Oct 2004 | A1 |
20040253183 | Uber, III et al. | Dec 2004 | A1 |
20040254533 | Schriver et al. | Dec 2004 | A1 |
20050107697 | Berke et al. | May 2005 | A1 |
20050171487 | Haury et al. | Aug 2005 | A1 |
20050234407 | Spohn et al. | Oct 2005 | A1 |
20050234428 | Spohn et al. | Oct 2005 | A1 |
20060052794 | Mcgill et al. | Mar 2006 | A1 |
20060079765 | Neer et al. | Apr 2006 | A1 |
20060079843 | Brooks | Apr 2006 | A1 |
20060167415 | Nemoto | Jul 2006 | A1 |
20070068964 | Tanaami et al. | Mar 2007 | A1 |
20070129705 | Trombley et al. | Jun 2007 | A1 |
20070161970 | Spohn et al. | Jul 2007 | A1 |
20070219496 | Kamen et al. | Sep 2007 | A1 |
20070276327 | Kalafut et al. | Nov 2007 | A1 |
20080015406 | Dlugos et al. | Jan 2008 | A1 |
20080045925 | Stepovich et al. | Feb 2008 | A1 |
20080086087 | Spohn et al. | Apr 2008 | A1 |
20080167621 | Wagner et al. | Jul 2008 | A1 |
20080183131 | Duchon et al. | Jul 2008 | A1 |
20090112164 | Reilly et al. | Apr 2009 | A1 |
20090216192 | Schriver et al. | Aug 2009 | A1 |
20090234226 | Nemoto | Sep 2009 | A1 |
20090247865 | Spohn et al. | Oct 2009 | A1 |
20090247961 | Carlyon | Oct 2009 | A1 |
20090312744 | Keeley et al. | Dec 2009 | A1 |
20100130809 | Morello | May 2010 | A1 |
20100222768 | Spohn et al. | Sep 2010 | A1 |
20100249586 | Cocker et al. | Sep 2010 | A1 |
20100262078 | Blomquist | Oct 2010 | A1 |
20100331779 | Nystrom et al. | Dec 2010 | A1 |
20110275988 | Davis et al. | Nov 2011 | A1 |
20120089114 | Hemond et al. | Apr 2012 | A1 |
20120101472 | Schroeder et al. | Apr 2012 | A1 |
20120123229 | Butterfield et al. | May 2012 | A1 |
20120123257 | Stokes, Jr. | May 2012 | A1 |
20120178629 | Hudson et al. | Jul 2012 | A1 |
20120203177 | Lanier, Jr. et al. | Aug 2012 | A1 |
20120204997 | Winn et al. | Aug 2012 | A1 |
20120217231 | Moore et al. | Aug 2012 | A1 |
20120245560 | Hochman | Sep 2012 | A1 |
20130030290 | Nemoto | Jan 2013 | A1 |
20130123619 | Griggs | May 2013 | A1 |
20130245439 | Small et al. | Sep 2013 | A1 |
20130245604 | Kouyoumjian et al. | Sep 2013 | A1 |
20130261993 | Ruchti et al. | Oct 2013 | A1 |
20140027009 | Riley et al. | Jan 2014 | A1 |
20140142537 | Gibson et al. | May 2014 | A1 |
20140276550 | Uram et al. | Sep 2014 | A1 |
20160030662 | Uber, III et al. | Feb 2016 | A1 |
20160278725 | Van Nijnatten | Sep 2016 | A1 |
20160331896 | Nemoto et al. | Nov 2016 | A1 |
20170035974 | Berry et al. | Feb 2017 | A1 |
20170056603 | Cowan et al. | Mar 2017 | A1 |
20170143898 | Grosse-Wentrup et al. | May 2017 | A1 |
20170258982 | Kemper | Sep 2017 | A1 |
20170290971 | Hedmann et al. | Oct 2017 | A1 |
20170343446 | Ciolkosz et al. | Nov 2017 | A1 |
20180133392 | Dembo et al. | May 2018 | A1 |
20190083699 | Spohn et al. | Mar 2019 | A1 |
Number | Date | Country |
---|---|---|
2045070 | Feb 1992 | CA |
2077712 | Dec 1993 | CA |
2234050 | Apr 1997 | CA |
1671428 | Sep 2005 | CN |
103347552 | Oct 2013 | CN |
3203594 | Aug 1983 | DE |
3726452 | Feb 1989 | DE |
4426387 | Aug 1995 | DE |
19702896 | Jul 1997 | DE |
19647701 | May 1998 | DE |
19919572 | Nov 2000 | DE |
0121216 | Oct 1984 | EP |
0129910 | Jan 1985 | EP |
0189491 | Aug 1986 | EP |
0192786 | Sep 1986 | EP |
0245160 | Nov 1987 | EP |
0319275 | Jun 1989 | EP |
0337924 | Oct 1989 | EP |
0343501 | Nov 1989 | EP |
0364966 | Apr 1990 | EP |
0365301 | Apr 1990 | EP |
0372152 | Jun 1990 | EP |
0378896 | Jul 1990 | EP |
0429191 | May 1991 | EP |
0471455 | Feb 1992 | EP |
0475563 | Mar 1992 | EP |
0595474 | May 1994 | EP |
0600448 | Jun 1994 | EP |
0619122 | Oct 1994 | EP |
0439711 | May 1995 | EP |
0869738 | Oct 1998 | EP |
1016427 | Jul 2000 | EP |
2990073 | Mar 2016 | EP |
2493708 | May 1982 | FR |
2561949 | Oct 1985 | FR |
201800 | Aug 1923 | GB |
2252656 | Aug 1992 | GB |
2328745 | Mar 1999 | GB |
S5017781 | Feb 1975 | JP |
S5815842 | Jan 1983 | JP |
S59214432 | Dec 1984 | JP |
S60194934 | Oct 1985 | JP |
S60194935 | Oct 1985 | JP |
S60253197 | Dec 1985 | JP |
S62216199 | Sep 1987 | JP |
S6340538 | Feb 1988 | JP |
S63290547 | Nov 1988 | JP |
H01207038 | Aug 1989 | JP |
H02224647 | Sep 1990 | JP |
H02234747 | Sep 1990 | JP |
H0355040 | Mar 1991 | JP |
H04115677 | Apr 1992 | JP |
H0584296 | Apr 1993 | JP |
H07178169 | Jul 1995 | JP |
H0849598 | Feb 1996 | JP |
H0999034 | Apr 1997 | JP |
H10211198 | Aug 1998 | JP |
2000175900 | Jun 2000 | JP |
2003102724 | Apr 2003 | JP |
2003116843 | Apr 2003 | JP |
2003210456 | Jul 2003 | JP |
2003225234 | Aug 2003 | JP |
2004174008 | Jun 2004 | JP |
2004236849 | Aug 2004 | JP |
2004298550 | Oct 2004 | JP |
4960180 | Jun 2012 | JP |
5063593 | Oct 2012 | JP |
5203971 | Jun 2013 | JP |
5227791 | Jul 2013 | JP |
5490840 | May 2014 | JP |
8001754 | Sep 1980 | WO |
8500292 | Jan 1985 | WO |
8803815 | Jun 1988 | WO |
9114232 | Sep 1991 | WO |
9114233 | Sep 1991 | WO |
9315658 | Aug 1993 | WO |
9325141 | Dec 1993 | WO |
9415664 | Jul 1994 | WO |
9632975 | Oct 1996 | WO |
9712550 | Apr 1997 | WO |
9820919 | May 1998 | WO |
9924095 | May 1999 | WO |
0061216 | Oct 2000 | WO |
0141835 | Jun 2001 | WO |
03015633 | Feb 2003 | WO |
2004012787 | Feb 2004 | WO |
2004035116 | Apr 2004 | WO |
2004091688 | Oct 2004 | WO |
2005016165 | Feb 2005 | WO |
2005035995 | Apr 2005 | WO |
2006042093 | Apr 2006 | WO |
2007079016 | Jul 2007 | WO |
2007092618 | Aug 2007 | WO |
2007116840 | Oct 2007 | WO |
2007116862 | Oct 2007 | WO |
2007116891 | Oct 2007 | WO |
2007133942 | Nov 2007 | WO |
2008078604 | Jul 2008 | WO |
2008106108 | Sep 2008 | WO |
2009051995 | Apr 2009 | WO |
2010027636 | Mar 2010 | WO |
2010117841 | Oct 2010 | WO |
2011002744 | Jan 2011 | WO |
2011097487 | Aug 2011 | WO |
2011125303 | Oct 2011 | WO |
2012048277 | Apr 2012 | WO |
2012155035 | Nov 2012 | WO |
2013043868 | Mar 2013 | WO |
2014144651 | Sep 2014 | WO |
2014179326 | Nov 2014 | WO |
2014190264 | Nov 2014 | WO |
2015106107 | Jul 2015 | WO |
2015164783 | Oct 2015 | WO |
2016112163 | Jul 2016 | WO |
2016172467 | Oct 2016 | WO |
2016191485 | Dec 2016 | WO |
2017012781 | Jan 2017 | WO |
2017038575 | Mar 2017 | WO |
2017096072 | Jun 2017 | WO |
2017152036 | Sep 2017 | WO |
2018060505 | Apr 2018 | WO |
2018075386 | Apr 2018 | WO |
2018089882 | May 2018 | WO |
Entry |
---|
Swiss; Medical Care., “CT Expres Contrast Media Delivery System Operation Manual Rev 1”, 2004. |
Angelini, P., “Use of mechanical injectors during percutaneous transluminal coronary angioplasty (PTCA),” Catheterization and Cardiovascular Diagnosis, vol. 16, Issue 3, pp. 193-194, Mar. 1989. |
Awai, K., et al., “Effect of contrast material injection duration and rate on aortic peak time and peak enhancement at dynamic CT involving injection protocol with dose tailored to patient weight,” Radiology, vol. 230, Issue 1, pp. 142-150, 2004. |
Bae, et al. “Aortic and Hepatic Contrast Medium Enhancement at CT—Part I, Prediction with a Computer Model”, Radiology 1998;207:647-655. |
Bae, K.T., et al., “Multiphasic Injection Method for Uniform Prolonged Vascular Enhancement at CT Angiography Pharmacokinetic Analysis and Experimental Porcine Model,” Radiology, vol. 216, Issue 3, pp. 872-880 (Sep. 2000). |
Bae, K.T. et al, “Peak Contrast Enhancement in CT and MR Angiography: When Does it Occur and Why? Pharmacokinetic Study in a Porcine Model”, Radiology, vol. 227, Jun. 2003, pp. 809-816. |
Bae, K.T., et al., “Uniform vascular contrast enhancement and reduced contrast medium vol. achieved by using exponentially decelerated contrast material injection method,” Radiology, vol. 231, Issue 3, pp. 732-736, 2004. |
Baker, Aaron; et al. “Fluid Mechanics Analysis of a Spring-Loaded Jet Injector.” IEEE Transactions on Biomedical Engineering, vol. 46, No. 2, Feb. 1999. |
Becker, C.R., et al., “Optimal contrast application for cardiac 4-detector-row computed tomography,” Investigative Radiology, vol. 38, Issue 11, pp. 690-694 (Nov. 2003). |
Blomley, M.J.K. and Dawson, P., “Bolus Dynamics: Theoretical and Experimental Aspects,” The Brit. J. ofRadiology, vol. 70, No. 832, pp. 351-359 (Apr. 1997). |
Brunette J.; et al., “Comparative rheology of low- and iso-osmolarity contrast agents at different temperature”, Catheterization and Cardiovascular Interventions, 2008, vol. 71 Issue No. 1, 78-83. |
Cademartiri, F. and Luccichenti, G., et al. “Sixteen-row multislice computed tomography: basic concepts, protocols, and enhanced clinical applications,” Seminars in Ultrasound, CT and MRI, vol. 25, Issue 1, pp. 2-16, 2004. |
Dardik, H. et al., “Remote Hydraulic Syringe Actuator,” Arch. Surg., vol. 115, Issue 1, Jan. 1980. |
Dawson, P. and Blomley, M., “The value of mathematical modelling in understanding contrast enhancement in CT with particular reference to the detection of hypovascular liver metastases,” European Journal of Radiology, vol. 41, Issue 3, pp. 222-236 (Mar. 2002). |
“Digital Injector for Angiography”, Sias. (Sep. 7, 1993). |
Disposable Low-Cost Catheter Tip Sensor Measures Blood Pressure during Surgery, Sensor (Jul. 1989). |
EZ Chem Brochure, E-Z-EM, Inc. (Jul. 2007). |
Fisher, M.E. and Teo, K.L., “Optimal insulin infusion resulting from a mathematical model of blood glucose dynamics”, IEEE Transactions on Biomedical Engineering, vol. 36, Issue 4, pp. 479-486, 1989. |
Flegal, K.M., et al., “Prevalence and trends in obesity among US adults,” JAMA, 2002, vol. 288, Issue 14, pp. 1-4, (1999-2000). |
Fleischmann, D. and Hittmair, K., “Mathematical analysis of arterial enhancement and optimization of bolus geometry for CT angiography using the discrete Fourier transform,” Journal of Computer Assisted Tomography, vol. 23, Issue 3, pp. 474-484 (May/Jun. 1999). |
Fleischmann, D., “Contrast Medium Injection Technique,” In: U. Joseph Schoepf: “Multidetector—Row CT of the Thorax,” pp. 47-59 (Jan. 22, 2004). |
Fleischmann, D., “Present and Future Trends in Multiple Detector—Row CT Applications; CT Angiography”, European Radiology, vol. 12, Issue 2, Supplement 2, Jul. 2002, pp. s11-s15. |
Gardiner, G. A., et al., “Selective Coronary Angiography Using a Power Injector,” AJR Am J Roentgenol., vol. 146, Issue 4, pp. 831-833 (Apr. 1986). |
Garrett, J. S., et al., “Measurement of cardiac output by cine computed tomography,” The American Journal of Cardiology, vol. 56, Issue 10, pp. 657-661, 1985. |
Gembicki, F.W., “Vector Optimization for Control with Performance and Parameter Sensitivity Indices,” PhD Thesis Case Western Reserve University, 1974. |
Gentilini A., et al., “A new paradigm for the closed-loop intraoperative administration of analgesics in humans,” IEEE Transactions on Biomedical Engineering, vol. 49, Issue 4, pp. 289-299 (Apr. 2002). |
Gerlowski L.E. and Jain R.K., “Physiologically Based Pharmacokinetic Modeling: Principles and Applications,” Journal of Pharmaceutical Sciences, vol. 72, pp. 1104-1125, Oct. 1983. |
Goss, J. E., et al., “Power injection of contrast media during percutaneous transluminal coronary artery angioplasty,” Catheterization and Cardiovascular Diagnosis, vol. 16, Issue 3, pp. 195-198 (Mar. 1989). |
Grant, S.C.D. et al., “Reduction of Radiation Exposure to the Cardiologist during Coronary Angiography by the Use of a Remotely Controlled Mechanical Pump for Injection of Contrast Medium,” Catheterization and Cardiovascular Diagnosis, vol. 25, Issue 2, pp. 107-109 (Feb. 1992). |
Hackstein, N. et al., “Glomerular Filtration Rate Measured by Using Triphasic Helical CT with a Two-Point Patlak Plot Technique,” Radiology, vol. 230, Issue 1, pp. 221-226, Jan. 2004. |
Hansen, P.C, Regularization tools: a MATLAB package for analysis and solution of discrete ill-posed problems, Numerical Algorithms, vol. 6, Issue 1, pp. 35, 1994. |
Hansen, P.C., “The truncated SVD as a method for regularization,” BIT Numerical Mathematics, vol. 27, Issue 4, pp. 534-555, 1987. |
Harris P., H. D. “The Human Pulmonary Circulation,” Edinburgh, Churchill Livingstone, (Appendix I), 1986. |
Hayes, M., “Statistical Digital Signal Processing and Modeling”, New York, New York, Wiley and Sons, 1996, pp. 154-177, (Prony's method). |
Heiken; J.P. et al., “Dynamic Contrast-Enhanced CT of the Liver: Comparison of Contrast Medium Injection Rates and Uniphasicand Biphasic Injection Protocols”, Radiology, May 1993, vol. 187, No. 2, pp. 327-331. |
“Infus O.R. Multi-Drug Syringe Pump with Smart Labels,” Bard MedSystems Division Inc., pp. 2693-2696 (2005). |
“International Preliminary Report on Patentability from PCT Application No. PCT/US2018/048283”, dated Mar. 12, 2020. |
Ireland, M.A., et al., “Safety and Convenience of a Mechanical Injector Pump for Coronary Angiography,”Catheterization and Cardiovascular Diagnosis, vol. 16, Issue 3, pp. 199-201 (1989). |
Jacobs, J.R, “Algorithm for optimal linear model-based control with application to pharmacokinetic model-driven drug delivery,” IEEE Transactions on Biomedical Engineering, vol. 37, Issue 1, pp. 107-109 (Jan. 1990). |
Korosec, F.R., “Physical Principles of Phase-Contrast, Time-of-Flight, and Contrast-Enhanced MR Angiography,” 41st Annual Meeting of American Association of Physicists in Medicine, Jul. 25-29, 1999. |
Korosec, Frank, “Basic Principles of Phase-contrast, Time-of-flight, and Contrast-enhanced MR Angiography”, 1999. |
Krause, W, “Application of pharmacokinetics to computed tomography: injection rates and schemes: mono-, bi-, or multiphasic?,” Investigative Radiology, vol. 31, Issue 2, pp. 91-100, Feb. 1996. |
Krieger, R. A., “CO2-Power-Assisted Hand-Held Syringe: Better Visualization during Diagnostic and InterventionalAngiography,” Cathet Cardiovasc Diagn., vol. 19, Issue 2, pp. 123-128 (Feb. 1990). |
Liebel-Flarsheim Company, “Angiomat 6000 Digital Injection System—Operator's Manual”, Document No. 600950, Rev. 1, Jan. 1990. |
Mahnken, A. H., et al., “Determination of cardiac output with multislice spiral computed tomography: a validation study,” Investigative Radiology, vol. 39, Issue 8, pp. 451-454, Aug. 2004. |
Mahnken, A. H., et al., “Measurement of cardiac output from a test-bolus injection in multislice computed tomography,” European Radiology, vol. 13, Issue 11, pp. 2498-2504, 2003. |
Mark V/Mark V Plus Injector Operation Manual KMP 805P Rev. B. Medrad, Inc, 1990. |
Mcclellan, J.H., “Parametric Signal Modeling,” Chapter 1 in Advanced Topics in Signal Processing, Pentice-Hall, Englewood Cliffs, NJ (1988). |
MCT and MCT Plus Injection Systems Operation Manual KMP 810P, Medrad, Inc, 1991. |
Morden Peter.; et al., “The Role of Saline Flush Injection Rate in Displacement of CT Injectable Peripherally Inserted Central Catheter Tip During Power Injection of Contrast Material”, AJR, Jan. 2014, 202, W13-W18. |
Neatpisarnvanit, C. and Boston, J.R., “Estimation of plasma insulin from plasma glucose”, IEEE Transactions on Biomedical Engineering, vol. 49, Issue 11, pp. 1253-1259, 2002. |
Ostergaard, L., et al., “High resolution measurement of cerebral blood flow using intravascular tracer boluspassages. Part 1: Mathematical approach and statistical analysis,” Magnetic Resonance in Medicine, vol. 36, Issue 5,pp. 715-725 (Nov. 1996). |
Ostergaard, L., et al., “High resolution measurement of cerebral blood flow using intravascular tracer boluspassages. Part II: Experimental comparison and preliminary results,” Magn Reson Med, vol. 36, Issue 5, pp. 726-736(Nov. 1996). |
Parker, K.J., et al., “A Particulate Contrast Agent With Potential for Ultrasound Imaging of Liver,” Ultrasound in Medicine & Biology, vol. 13, Issue 9, pp. 555-566 (Sep. 1987). |
Rosen, B.R. et al., “Perfusion Imaging with NMR Contrast Agents,” Magentic Resonance in Medicine, vol. 14, No. 2, pp. 249-265, May 1, 1990. |
Sablayrolles, J-L, “Cardiac CT: Experience from Daily Practice”, Advance CT, A GE Healthcare Publication. Aug. 2004. |
Stevens, M.A., et al. “A Prospective Randomized Trial of Prevention Measures in Patients at High Risk for Contrast Nephropathy,” J. of the ACC, vol. 33, Issue 2, pp. 403-411, Feb. 1999. |
“The Solution for Your IV Formulas”, Valley Lab. Inc., E-39-15, 3399, 3400, 2646. |
Wada D.R. and Ward; D.S., “The hybrid model: a new pharmacokinetic model for computer-controlled infusion pumps”, IEEE Transactions on Biomedical Engineering, 1994, vol. 41, Issue 2, pp. 134-142. |
Wada, D.R. and Ward, D.S., “Open loop control of multiple drug effects in anesthesia”, IEEE Transactions on Biomedical Engineering, vol. 42, Issue 7, pp. 666-677, 1995. |
Yamashita, Y. et al., “Abdominal Helical CT: Evaluation of Optimal Doses of Intravenous Contrast Material—A Prospective Randomized Study,” Radiology, vol. 216, Issue 3, pp. 718-723, Sep. 1, 2000. |
Angiography, Catheterization and Cardiovascular Diagnosis, vol. 19, pp. 123-128, 1990. |
Awai Kazuo; et al, “Aortic and Hepatic Enhancement and Tumor-to-Liver Contrast Analysis of the Effect of Different Concentrations of Contrast Material at Multi-Detector Row Helical CT.”, Radiology, 2002, vol. 224; Issue 3., 757-763. |
Number | Date | Country | |
---|---|---|---|
20200114074 A1 | Apr 2020 | US |
Number | Date | Country | |
---|---|---|---|
62552433 | Aug 2017 | US |